Use of Deep-Amplicon Sequencing (DAS), Real-Time PCR and In Situ Hybridization to Detect H. pylori and Other Pathogenic Helicobacter Species in Feces from Children

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Moreno Trigos, Yolanda
  • Simo-Jorda, Raquel
  • Hernandez Perez, Manuel
  • Hortelano, Irene
  • Garcia-Ferrus, Miguel
  • Ferrus Perez, Maria Antonia

Grups d'Investigació

Abstract

Background: Detecting Helicobacter pylori in fecal samples is easier and more comfortable than invasive techniques, especially in children. Thus, the objective of the present work was to detect H. pylori in feces from children by molecular methods as an alternative for diagnostic and epidemiological studies. Methods: Forty-five fecal samples were taken from pediatric patients who presented symptoms compatible with H. pylori infection. HpSA test, culture, real-time quantitative PCR (qPCR), fluorescence in situ hybridization (FISH), direct viable count associated with FISH (DVC-FISH), and Illumina-based deep-amplicon sequencing (DAS) were applied. Results: No H. pylori colonies were isolated from the samples. qPCR analysis detected H. pylori in the feces of 24.4% of the patients. In comparison, DVC-FISH analysis showed the presence of viable H. pylori cells in 53.3% of the samples, 37% of which carried 23S rRNA mutations that confer resistance to clarithromycin. After DAS, H. pylori-specific 16S rDNA sequences were detected in 26 samples. In addition, DNA from H. hepaticus was identified in 10 samples, and H. pullorum DNA was detected in one sample. Conclusion: The results of this study show the presence of H. pylori, H. hepaticus, and H. pullorum in children's stools, demonstrating the coexistence of more than one Helicobacter species in the same patient. The DVC-FISH method showed the presence of viable, potentially infective H. pylori cells in a high percentage of the children's stools. These results support the idea that fecal-oral transmission is probably a common route for H. pylori and suggest possible fecal-oral transmission of other pathogenic Helicobacter species.

Dades de la publicació

ISSN/ISSNe:
2075-4418, 2075-4418

DIAGNOSTICS  MDPI AG

Tipus:
Article
Pàgines:
-
PubMed:
38928632
Factor d'Impacte:
0,658 SCImago
Quartil:
Q2 SCImago

Documents

  • No hi ha documents

Mètriques

Filiacions

Filiacions no disponibles

Keywords

  • Helicobacter pylori; non-pylori helicobacters; real-time PCR; in situ hybridization; deep-amplicon sequencing (DAS); feces; children

Campos d'Estudi

Projectes associats

Identificación de biomarcadores inmunológicos en pacientes alérgicos.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

LET-INM-2020 . 2023

Ensayo clínico de eficacia y seguridad, prospectivo, multicéntrico, aleatorizado, doble ciego controlado con placebo, con inmunoterapia subcutánea en pacientes con rinitis/rinoconjuntivitis con o sin asma de leve a moderada sensibilizados a Dermatophagoides pteronyssinus y/o Dermatophagoides farinae.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

MM09-SIT-023 . 2023

A virtual, decentralised observational follow-up study investigating feeding patterns in infancy and the associated parent-reported allergic manifestations, allergies and infections in childhood.

Investigador Principal: JUAN PABLO FERRER GONZÁLEZ

EBB18TA23570 . 2024

Evaluación de la eficacia y seguridad de la inmunoterapia subcutánea (Beltavac®) con extracto alergénico polimerizado de mezcla de ácaros del polvo en pacientes con rinitis/rinoconjuntivitis alérgica.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

2023

Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad a largo plazo de dupilumab en niños de 2 a <6 años con asma no controlada y/o sibilancias asmáticas graves recurrentes.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

EFC14771 . 2024

Estudio fase III multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo de la eficacia y la seguridad de tezepelumab en niños de 5 a <12 años con asma grave no controlada (HORIZON).

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

D5180C00016 . 2024

Compartir la publicació